Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Zobrazit další vydání (1)

OBJECTIVE: To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). METHODS: Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial la...

Podrobná bibliografie
Hlavní autoři:	Elliott, M, Maini, R, Feldmann, M, Long-Fox, A, Charles, P, Katsikis, P, Brennan, F, Walker, J, Bijl, H, Ghrayeb, J
Médium:	Journal article
Jazyk:	English
Vydáno:	1993

Podobné jednotky

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
Autor: Elliot, M, a další
Vydáno: (2008)

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.
Autor: Elliott, M, a další
Vydáno: (1994)

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
Autor: Elliott, M, a další
Vydáno: (1994)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
Autor: Brennan, F, a další
Vydáno: (1995)

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
Autor: Paleolog, E, a další
Vydáno: (1996)

TNF alpha as a therapeutic target in rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1994)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
Autor: Maini, R, a další
Vydáno: (1995)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1997)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1994)

Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
Autor: Feldmann, M, a další
Vydáno: (1997)

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Autor: Maini, R, a další
Vydáno: (1999)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
Autor: Maini, R, a další
Vydáno: (1994)

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Autor: Maini, R, a další
Vydáno: (1998)

Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.
Autor: Davis, D, a další
Vydáno: (1997)

Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1992)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1995)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
Autor: Maini, R, a další
Vydáno: (1995)

Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus.
Autor: Maini, R, a další
Vydáno: (1994)

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.
Autor: Tak, P, a další
Vydáno: (1996)

Immunoregulatory role of interleukin 10 in rheumatoid arthritis.
Autor: Katsikis, P, a další
Vydáno: (1994)

TNF alpha--a pivotal role in rheumatoid arthritis?
Autor: Brennan, F, a další
Vydáno: (1992)

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.
Autor: Haworth, C, a další
Vydáno: (1991)

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Autor: Charles, P, a další
Vydáno: (2000)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
Autor: Feldmann, M
Vydáno: (1996)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
Autor: Maini, R, a další
Vydáno: (1998)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (2001)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
Autor: Feldmann, M, a další
Vydáno: (1995)

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.
Autor: Taylor, P, a další
Vydáno: (2000)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Autor: Maini, R, a další
Vydáno: (1999)

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.
Autor: Chu, C, a další
Vydáno: (1991)

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.
Autor: Deleuran, B, a další
Vydáno: (1992)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
Autor: Maini, R, a další
Vydáno: (1993)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
Autor: Elliott, M, a další
Vydáno: (1995)

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
Autor: Brennan, F, a další
Vydáno: (1997)

Rheumatoid arthritis.
Autor: Feldmann, M, a další
Vydáno: (1996)

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.
Autor: Brennan, F, a další
Vydáno: (1989)

Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis.
Autor: Deleuran, B, a další
Vydáno: (1992)

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Autor: Ulfgren, A, a další
Vydáno: (2000)

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
Autor: Paleolog, E, a další
Vydáno: (1998)

Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
Autor: Butler, D, a další
Vydáno: (1995)